November 15, 2022

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

November 10, 2022

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

September 22, 2022

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

August 12, 2022

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

August 2, 2022

Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

June 29, 2022

Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

May 26, 2022

Appili Therapeutics Announces Closing of Public Offering of $4,500,000

May 18, 2022

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

May 17, 2022

Appili Therapeutics Announces Overnight Marketed Equity Offering

April 27, 2022

Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

April 13, 2022

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

March 29, 2022

Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings

March 9, 2022

Appili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor Forum

February 28, 2022

Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

February 14, 2022

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022

February 8, 2022

Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals